Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8232389 | 0.73 | ALDH1A1 (0.45) | KDM4ESMN1; SMN2MAPTALDH1A1CYP1A2 | |
| SCHEMBL7944009 | 0.69 | METAP1 (0.50) | KDM4EMAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL2849831 | 0.69 | PDE3B (0.53) | KDM4EALDH1A1HPGDCYP1A2CYP3A4 | |
| SCHEMBL31069587 | 0.69 | PDE3B (0.53) | KDM4EALDH1A1HPGDCYP1A2CYP3A4 | |
| SCHEMBL9638313 | 0.69 | MAPT (0.60) | KDM4ESMN1; SMN2MAPTMAPK1BACE1 | |
| SCHEMBL11192923 | 0.67 | BACE1 (0.66) | KDM4ESMN1; SMN2MAPTMAPK1BACE1 | |
| SCHEMBL26338303 | 0.67 | CYP11B1 (0.43) | KDM4ESMN1; SMN2MAPTBACE1ALDH1A1 | |
| SCHEMBL29402037 | 0.66 | PTPN1 (0.57) | KDM4ESMN1; SMN2MAPTMAPK1BACE1 | |
| SCHEMBL12325013 | 0.66 | PTPN1 (0.57) | KDM4ESMN1; SMN2MAPTMAPK1BACE1 | |
| SCHEMBL5551697 | 0.66 | PTPN1 (0.57) | KDM4ESMN1; SMN2MAPTMAPK1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324994-A4 | TRICYCLIC COMPOUNDS AND USES THEREOF | CALYX THERAPEUTICS INC (US) | 2004-06-16 | — | — | EP | claimed |
| US-6723736-B2 | FOR THERAPY INFLAMMATION, INFLAMMATORY DISEASES, IMMUNOLOGIC DISEASES AND OTHER DISEASES MEDIATED BY TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) AND/OR INTERLEUKIN 6 OR 10 AND/OR ENZYME CYCLOOXYGENASE-2 (COX-2) | THERACOS, INC. | 2004-04-20 | — | — | US | claimed |
| EP-1324994-A2 | TRICYCLIC COMPOUNDS AND USES THEREOF | Calyx Therapeutics, Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020077333-A1 | Tricyclic compounds and uses thereof | THERACOS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2002030888-A2 | TRICYCLIC COMPOUNDS AND USES THEREOF | CALYX THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077333-A1 | Tricyclic compounds and uses thereof | IL6, TNF, IL2 | NPY5R 4563/4885KDM4E 3276/4885SMN1; SMN2 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.